19357-10-9

Upstream product

• 504-29-0 2-aminopyridine 
• 85-44-9 phthalic anhydride 
• 59208-49-0 N-(2-pyridinyl)phthalimide 
• 88-95-9 Phthaloyl dichloride 
• 13699-68-8 3-thioxo-3H-isobenzofuran-1-one 
• 136918-14-4 phthalimide 

Downstream Products

• 179470-27-0 Pd(C₁₃H₁₀N₂O₃)2Cl₂ 

Relevant academic research and scientific papers

Compounds and methods for inducing chondrogenesis

The present invention provides compounds and compositions for the amelioration of arthritis and joint injuries by inducing mesenchymal stem cells into chondrocytes.

Metal-pyridylcarboxypropanamide (PCPAH) and metal-pyridylcarboxybenzamide (PCBAH) interactions: Stability constant, chemical speciation and molecular modelling studies

Chemical speciation and molecular modelling studies have been carried out for accessing the interactions of metal ion with some amide containing ligands. Chemical speciation has been carried out using the program BEST and SPE and method of Bjerrum and Calvin, as modified by Irving and Rassotti has been used to find out the values of stability constants. The order of stability constants is found to be fairly in agreement to Irving-Williams order. Molecular modelling studies have been carried out to determine the ideal site for metal binding to the ligands PCPAH and PCBAH.

New anti-inflammatory N-pyridinyl(alkyl)phthalimides acting as tumour necrosis factor-α production inhibitors

This paper describes the synthesis of N-pyridinyl(alkyl)phthalimides related to N-phenyl-4,5,6,7-tetrafluorophthalimides known to be inhibitors of tumour necrosis factor-α (TNFα) production. Pharmacomodulation at the phthalimidic nitrogen led to the selection of two pharmacophoric fragments (2,4-lutidinyl and β-picolyl), allowing significant inhibition of TNFα production (compounds 12 and 17). Variation of the substituents linked to the homocycle of their phthalimide scaffold indicated that high (TNFα production) inhibitory potency could be achieved, notably by 5-fluoro, 4- or 5-nitro, 5-amino and especially tetrafluoro substitution. The most active compound, N-(pyridin-3-ylmethyl)-4,5,6,7-tetrafluorophthalimide (32) (84% inhibition at 10 μM), also produced an anti-oedematous effect in the PMA-induced mouse-ear swelling test. Although less active than dexamethasone, it exerted a marked reduction in ear thickness after oral administration (63% vs. 85% for dexamethasone at 0.2 mM kg-1) and remained efficient after topical application (46% vs. 96% for the dexamethasone). It also induced potent inhibition in the rat carrageenan foot oedema test with an ID50 (0.14 μM kg-1) comparable with that of N-(2,6-diisopropylphenyl)phthalimide (4) (0.15 μM kg-1).

Synthesis and potent tumour necrosis factor-α production inhibitory activity of N-pyridinylphthalimides and derivatives

A series of N-azaaryl(alkyl)phthalimides incorporating amino(alkyl)pyridines were synthesized and tested as inhibitors of TNF-α production. The most potent compounds were N-(4,6-dimethyl-pyridin-2-yl)tetrafluorophthalimide (8, 40% inhibition at 10 μM), N-(3-methylpyridinyl)-5-fluorophthalimide (12, 48%) and N-(3-methylpyridinyl)tetrafluorophthalimide (13, 68%). The analogues without (tetra)fluorine substitution on the aromatic ring were less active inhibitors.